Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Opyl Ltd. ( (AU:PKY) ) has provided an update.
Pathkey.AI Ltd announced that its TrialKey platform continues to demonstrate strong predictive capabilities in identifying clinical trials with above-average success probabilities. In September 2025, four new inflection events were observed, with an average share price change of +43.6% from TrialKey observation to post-readout inflection. The company is actively monitoring eleven programs with an average return of 16.7% on stocks yet to report outcomes. These insights are being utilized across various sectors, reinforcing the platform’s value in improving clinical trial success predictions.
More about Opyl Ltd.
Pathkey.AI Ltd, listed on the ASX under the ticker PKY, operates in the biotechnology sector. The company offers TrialKey, an artificial intelligence platform that analyzes global clinical trial data to estimate the Probability of Success (PoS) for various indications and phases. TrialKey’s insights are applied in trial optimization, insurance, and biotech investing, with partnerships such as the one with L39 Capital’s AI Biotech Fund.
Average Trading Volume: 864,421
Technical Sentiment Signal: Sell
Current Market Cap: A$7.57M
For detailed information about PKY stock, go to TipRanks’ Stock Analysis page.